Poop pills could supercharge lung cancer therapy
NCT ID NCT07247786
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether fecal transplants from immunotherapy responders can improve outcomes in stage II-III non-small cell lung cancer. 68 patients will receive either standard treatment (Durvalumab + chemotherapy) or the same plus fecal transplant capsules. The main goal is to see if the transplant increases the rate of complete tumor disappearance after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fecal microbiota transplant (FMT) capsules
What this could lead to
If it works, this could point toward a way to boost the effectiveness of standard lung cancer therapy by using healthy gut bacteria from patients who responded well to immunotherapy.
What could go wrong
This is a small, early-phase trial (68 patients) testing safety and feasibility first. The approach is experimental, and it is unknown if the transplant will meaningfully improve outcomes or cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Complexo Hospitalario Universitario De Santiago
Santiago de Compostela, La Coruña, 15706, Spain
-
Complexo Hospitalario Universitario De Vigo
Vigo, Vigo, 36204, Spain
-
Hospital Clinico San Carlos
Madrid, Madrid, 28040, Spain
-
Hospital Clínico de Valencia
Valencia, Valencia, 46010, Spain
-
Hospital General Universitario De Elche
Elche, Alicante, 03203, Spain
-
Hospital General Universitario Morales Meseguer
Murcia, Murcia, 30008, Spain
-
Hospital General Universitario de Alicante
Alicante, Alicante, 03010, Spain
-
Hospital Universitari Quiron Dexeus
Barcelona, Barcelona, 08028, Spain
-
Hospital Universitari Vall d' Hebron
Barcelona, Barcelona, 08035, Spain
-
Hospital Universitario 12 De Octubre
Madrid, Madrid, 28041, Spain
-
Hospital Universitario Clínico San Cecilio
Granada, Granada, 18007, Spain
Contact
Contact
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, Madrid, 28040, Spain
-
Hospital Universitario La Fe
Valencia, Valencia, 46026, Spain
-
Hospital Universitario Lucus Augusti
Lugo, Lugo, 27003, Spain
-
Hospital Universitario Nuestra Señora de Candelaria
Santa Cruz de Tenerife, Santa Cruz de Tenerife, 38010, Spain
-
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, 28222, Spain
-
Hospital Universitario Regional de Málaga
Málaga, Málaga, 29010, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, 08041, Spain
-
ICO Badalona, Hospital Germans Trias i Pujol
Badalona, Barcelona, 08916, Spain
-
ICO Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain